AHNS成员对p16阴性/HPV阴性口咽鳞癌治疗模式的调查
该横断面调查通过在线问卷了解美国头颈学会(AHNS)成员对p16阴性/HPV阴性口咽鳞癌的治疗实践。108名成员(占7.7%)回应,多数有≥5年经验。57.4%认为手术生存优于非手术治疗,56.5%对可切除T1-T3常选TORS,治疗强化使用差异大。
要点
- 多数AHNS外科医生认为p16阴性/HPV阴性口咽癌手术生存更优。
- 经口机器人手术(TORS)常用于可切除T1-T3及原发灶不明颈部转移。
- 辅助治疗强化模式差异大,反映领域知识缺口。
核心结论
- 多数AHNS外科医生(57.4%)认为p16阴性/HPV阴性口咽鳞癌手术生存优于非手术根治治疗。
- 大多数(56.5%)对可切除T1-T3肿瘤选择TORS,少数(26.8%)对T3-T4常或总是手术。
- 治疗强化使用差异大,存在领域知识缺口。
研究设计与样本
- 横断面在线电子问卷调查。
- 通过AHNS调查系统分发,自愿匿名参与。
- 108名AHNS成员回应,占会员7.7%;65.7%有≥5年领域经验。
主要发现
- 23.2%总是、10.2%经常用DNA/RNA原位杂交或PCR确认p16阴性肿瘤的HPV阴性状态。
- 60.2%报告对p16-/HPV阴性颈部肿块患者推荐TORS寻找原发灶。
- 56.5%总是或经常对可切除T1-T3采用TORS。
- 73.2%不常(59.3%)或从不(13.9%)将传统开放手术作为T3/T4一线治疗。
- 治疗强化(T1-2N0双模式辅助或T1-T2N1三模式)使用:19.4%从不、36.1%不常、34.3%经常、10.2%总是。
临床怎么用
- 调查显示多数AHNS外科医生倾向以手术(尤其TORS)治疗p16阴性/HPV阴性口咽鳞癌可切除病例。
- 对T3/T4肿瘤,多数不将传统开放手术作为一线,治疗强化选择差异大,需个体化决策。
局限性
- 回应率低(7.7%),可能存在选择偏倚。
- 横断面调查仅反映实践模式,非临床结局。
- 数据为匿名自报,未经验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate practice patterns in the treatment of p16-negative/human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) among members of the American Head and Neck Society (AHNS). STUDY DESIGN: Cross-sectional. SETTING: Online electronic survey. METHODS: An online survey was distributed via AHNS survey system. Participation was voluntary, and data were anonymously collected. RESULTS: 108 members (7.7% of AHNS members) responded. Most (65.7%) had ≥5 years of experience in the field. Few practitioners (23.2% always and 10.2% frequently) confirmed HPV-negative status with DNA/RNA in situ hybridization or PCR testing for p16-negative tumors. Most surgeons (60.2%) reported recommending TORS for identification of an unknown primary in a patient with p16-/HPV-negative neck mass. Similarly, at least half (56.5%) of surgeons indicated always or frequently treating resectable T1-T3 with TORS. The majority (73.2%) of surgeons indicated infrequently (59.3%) or never (13.9%) treating T3/T4 with traditional open surgery as first line. More than half of the surgeons (57.4%) believed survival is better with surgery compared to definitive nonsurgical therapy for HPV-negative OPSCC. There was wide variation in the use of treatment intensification (dual modality adjuvant treatment for T1-2N0, or tri-modality treatment for T1-T2N1), with 19.4% reporting never, 36.1% infrequently, 34.3% frequently, and 10.2% always doing so. CONCLUSIONS: A majority of AHNS surgeons (57.4%) believe survival for HPV-negative OPSCC is better with surgery. Most (56.5%) would treat resectable T1-T3 tumors with TORS, while the minority (26.8%) would frequently or always operate on T3-T4 tumors. There was wide variation in practice with respect to treatment intensifiication owing to remaining knowledge gaps in the field.
引用
- Bulbul MG, de Almeida JR, Gross ND, et al. Treatment of P16-Negative/HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Survey of AHNS Membership. Otolaryngol Head Neck Surg. 2026. PMID: 41609382. doi:10.1002/ohn.70150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。